PROK

ProKidney Corp.
CAPPED RATING

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp. (PROK) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.6 / 5.0
D+
Value
F
Factor Score 0.3 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.4
EV / EBITDA -6.3
Rev Growth YoY -19.8%
Gross Margin N/M
Price Return 3M -25.4%
Price Return 12M -61.0%
Catalyst Signal 0.00
Market Cap $417.2M
TTM Revenue $775.0K
Price / Sales 538.3
ROE -73.4%

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 F (0.3) D (1.2) D (1.5) C (2.2) C+ (2.6) D+ (1.6)
2026-11-07 F (0.3) D (1.4) D (1.3) C- (2.1) C+ (2.7) D+ (1.6)
2026-10-31 F (0.1) D (1.4) D (1.3) C (2.2) C+ (2.7) D+ (1.6)
2026-10-24 F (0.1) D (1.4) D (1.3) C (2.2) C+ (2.6) D+ (1.5)
2026-10-17 F (0.2) D (1.4) D (1.3) C- (2.1) C+ (2.6) D+ (1.5)
Page 1 of 3